M&A Deal Summary

ANI Pharmaceuticals Acquires Alimera Sciences

On June 24, 2024, ANI Pharmaceuticals acquired life science company Alimera Sciences for 381M USD

Acquisition Highlights
  • This is ANI Pharmaceuticals’ 13th transaction in the Life Science sector.
  • This is ANI Pharmaceuticals’ largest (disclosed) transaction.
  • This is ANI Pharmaceuticals’ 12th transaction in the United States.
  • This is ANI Pharmaceuticals’ 1st transaction in Georgia.

M&A Deal Summary
Date 2024-06-24
Target Alimera Sciences
Sector Life Science
Buyer(s) ANI Pharmaceuticals
Deal Type Merger
Deal Value 381M USD
Advisor(s) Centerview Partners
Perella Weinberg Partners (Financial)
DLA Piper (Legal)

Target

Alimera Sciences

Alpharetta, Georgia, United States
Alimera Sciences is a biopharmaceutical company specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company is focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies. Alimera Sciences was founded in 2003 and is based in Alpharetta, Georgia.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ANI Pharmaceuticals

Baudette, Minnesota, United States
Category Company
Founded 2001
Sector Life Science
Employees642
Revenue 487M USD (2023)
DESCRIPTION

ANI Pharmaceuticals is a developer, manufacturer, and marketer of top-quality prescription pharmaceuticals. In two facilities with combined manufacturing, packaging, and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder, and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. ANI Pharmaceuticals was formed in 2001 and is based in Baudette, Minnesota.

DEAL STATS #
Overall 15 of 15
Sector (Life Science) 13 of 13
Type (Merger) 2 of 2
State (Georgia) 1 of 1
Country (United States) 12 of 12
Year (2024) 1 of 1
Size (of disclosed) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-09 Novitium Pharma

East Windsor, New Jersey, United States

With operations in East Windsor, New Jersey, and Chennai, India, Novitium Pharma is a U.S.-based pharmaceutical company that specializes in the development, manufacturing, and distribution of niche generic products. The Company, founded in 2016, by Samy Shanmugam, Chad Gassert, and Vijay Thorappadi, has since developed a growing commercial product portfolio spanning a diverse range of dosage forms and therapeutic categories.

Buy $164M
Mergr

Product

Company

Legal